Lexeo Therapeutics to present LX2006 neurologic data at MDS 2026
LXEO•Lexeo Therapeutics said it will present new neurological subscore analyses of its LX2006 Friedreich ataxia gene therapy at MDS 2026 in Seoul on Oct. 7, including previously reported findings of possible early stabilization or improvement versus a matched natural-history cohort.
1. Presentation planned
Lexeo Therapeutics flagged an upcoming oral presentation on LX2006 at MDS 2026 in Seoul, scheduled for Oct. 7, 2026. The update will include previously reported findings suggesting early stabilization or improvement in neurological function versus a matched natural-history cohort, with new analyses breaking out neurological subscores.
